PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting
Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who unde...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/93229 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/93229 |
| Access Level: | acceso abierto |
| Palabra clave: | 617.7-007.681 617.7-089 Glaucoma Glaucoma surgery Intraocular pressure MIGS, Ologen Preserflo MicroShunt Oftalmología Cirugía 3201.09 Oftalmología 3213.09 Cirugía Ocular |
| id |
ES_8bcfcfd86c6339097fc0ad4e51f76143 |
|---|---|
| oai_identifier_str |
oai:docta.ucm.es:20.500.14352/93229 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical settingRojo Arnao, MaríaMartínez De La Casa Fernández-Borrella, José MaríaAlbis Donado, ÓscarYáñez Castro, GiovanniMaroto Cejudo, RaquelTéllez, JesúsMenoyo Calatayud, Ricardo617.7-007.681617.7-089GlaucomaGlaucoma surgeryIntraocular pressureMIGS, OlogenPreserflo MicroShuntOftalmologíaCirugía3201.09 Oftalmología3213.09 Cirugía OcularPurpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months (P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg (P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg (P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population (P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.Wolters KluwerUniversidad Complutense de Madrid20232023-12-2620232023-12-26journal articlehttp://purl.org/coar/resource_type/c_6501AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/93229reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/932292026-06-02T12:44:21Z |
| dc.title.none.fl_str_mv |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| spellingShingle |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting Rojo Arnao, María 617.7-007.681 617.7-089 Glaucoma Glaucoma surgery Intraocular pressure MIGS, Ologen Preserflo MicroShunt Oftalmología Cirugía 3201.09 Oftalmología 3213.09 Cirugía Ocular |
| title_short |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_full |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_fullStr |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_full_unstemmed |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| title_sort |
PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting |
| dc.creator.none.fl_str_mv |
Rojo Arnao, María Martínez De La Casa Fernández-Borrella, José María Albis Donado, Óscar Yáñez Castro, Giovanni Maroto Cejudo, Raquel Téllez, Jesús Menoyo Calatayud, Ricardo |
| author |
Rojo Arnao, María |
| author_facet |
Rojo Arnao, María Martínez De La Casa Fernández-Borrella, José María Albis Donado, Óscar Yáñez Castro, Giovanni Maroto Cejudo, Raquel Téllez, Jesús Menoyo Calatayud, Ricardo |
| author_role |
author |
| author2 |
Martínez De La Casa Fernández-Borrella, José María Albis Donado, Óscar Yáñez Castro, Giovanni Maroto Cejudo, Raquel Téllez, Jesús Menoyo Calatayud, Ricardo |
| author2_role |
author author author author author author |
| dc.contributor.none.fl_str_mv |
Universidad Complutense de Madrid |
| dc.subject.none.fl_str_mv |
617.7-007.681 617.7-089 Glaucoma Glaucoma surgery Intraocular pressure MIGS, Ologen Preserflo MicroShunt Oftalmología Cirugía 3201.09 Oftalmología 3213.09 Cirugía Ocular |
| topic |
617.7-007.681 617.7-089 Glaucoma Glaucoma surgery Intraocular pressure MIGS, Ologen Preserflo MicroShunt Oftalmología Cirugía 3201.09 Oftalmología 3213.09 Cirugía Ocular |
| description |
Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months (P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg (P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg (P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population (P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2023-12-26 2023 2023-12-26 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 AM http://purl.org/coar/version/c_ab4af688f83e57aa |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/20.500.14352/93229 |
| url |
https://hdl.handle.net/20.500.14352/93229 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-ShareAlike 4.0 International http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-ShareAlike 4.0 International http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Wolters Kluwer |
| publisher.none.fl_str_mv |
Wolters Kluwer |
| dc.source.none.fl_str_mv |
reponame:Docta Complutense instname:Universidad Complutense de Madrid (UCM) |
| instname_str |
Universidad Complutense de Madrid (UCM) |
| reponame_str |
Docta Complutense |
| collection |
Docta Complutense |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869412852994932736 |
| score |
15,300719 |